Elevance Health, Inc. $ELV Shares Purchased by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 3.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 470,386 shares of the company’s stock after buying an additional 15,375 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Elevance Health were worth $166,634,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock worth $7,431,322,000 after purchasing an additional 141,747 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Elevance Health by 4.8% during the third quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock worth $2,139,473,000 after buying an additional 303,099 shares during the period. Artisan Partners Limited Partnership grew its holdings in shares of Elevance Health by 24.5% during the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after buying an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC raised its stake in Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the last quarter. Finally, Invesco Ltd. lifted its position in Elevance Health by 22.9% during the 3rd quarter. Invesco Ltd. now owns 2,597,488 shares of the company’s stock worth $839,300,000 after acquiring an additional 484,303 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $374.84 on Thursday. The company has a market capitalization of $81.40 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 2.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The company’s fifty day moving average price is $312.00 and its 200 day moving average price is $331.96. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $424.24.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the prior year, the firm posted $11.97 earnings per share. The company’s revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ELV. Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Citigroup raised shares of Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. UBS Group set a $400.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Wells Fargo & Company cut their price objective on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research note on Friday, January 30th. Finally, Barclays raised their target price on shares of Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a report on Friday, April 24th. Thirteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.